Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Public ClinicalTrials.gov record NCT07286058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 \[NCT06671483\] or TAK-279-PsA-3002 \[NCT06671496\]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD). Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.
Study identification
- NCT ID
- NCT07286058
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,182 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 10, 2026
- Primary completion
- Dec 17, 2029
- Completion
- Dec 17, 2029
- Last update posted
- Aug 2, 2026
2026 – 2029
United States locations
- U.S. sites
- 17
- U.S. states
- 7
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| First OC Dermatology Research Inc. | Fountain Valley | California | 92708 | Recruiting |
| Purushotham & Akther Kotha MD | La Mesa | California | 91942 | Recruiting |
| Triwest Research Associates LLC | La Mesa | California | 91942 | Recruiting |
| The Cohen Medical Centers | Thousand Oaks | California | 91360-3967 | Recruiting |
| Denver Arthritis Clinic - Lowry | Denver | Colorado | 80230 | Recruiting |
| Direct Helpers Research Center | Hialeah | Florida | 33012 | Recruiting |
| Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research | Hialeah | Florida | 33016 | Recruiting |
| IRIS Research and Development | Plantation | Florida | 33324 | Recruiting |
| Klein and Associates, M.D., P.A. | Hagerstown | Maryland | 21740-6138 | Recruiting |
| Paramount Medical Research & Consulting, LLC | Middleburg Heights | Ohio | 44130 | Recruiting |
| West Tennessee Research Institute | Jackson | Tennessee | 38305 | Recruiting |
| Accurate Clinical Research | Baytown | Texas | 77521 | Recruiting |
| Novel Research LLC | Bellaire | Texas | 77401 | Recruiting |
| Novel Research | Abigail Neiman - Houston, TX | Houston | Texas | 77024 | Recruiting |
| Northwest Houston Arthritis Center | Houston | Texas | 77090 | Recruiting |
| West Texas Clinical Research | Lubbock | Texas | 79424 | Recruiting |
| Advanced Rheumatology of Houston | The Woodlands | Texas | 77382united | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07286058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2026 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07286058 live on ClinicalTrials.gov.